Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Zepzelca (lurbinectedin) is indicated for the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.
• This summary is based on the review of two systematic review(s)/meta-analysis(es). ^[1-2]
• Lurbinectedin demonstrated a survival benefit in platinum-sensitive small-cell lung cancer (SCLC) patients compared to oral topotecan (HR 0.43, 95% CrI: 0.27, 0.67), intravenous topotecan (HR 0.43, 95% CrI: 0.26, 0.70), and platinum re-challenge (HR 0.42, 95% CrI: 0.30, 0.58).
• The effectiveness outcomes highlighted the superior overall survival of lurbinectedin compared to oral and intravenous topotecan and platinum re-challenge in platinum-sensitive SCLC patients.
• Lurbinectedin demonstrated a favorable safety profile compared to oral and IV topotecan, and platinum re-challenge in platinum-sensitive SCLC patients, with no detailed adverse effects provided in the studies.
• There were no specific safety concerns or adverse effects highlighted in the reviewed studies.
• There is no population types or subgroups information available in the reviewed studies.